Welcome to www.pliva.com

PLIVA Announces FDA Approval of SANCTURA

PLIVA d.d. (“PLIVA”) announced today that the US Food and Drug Administration (FDA) has approved SANCTURA™ (trospium chloride tablets), which is indicated for the treatment of overactive bladder (OAB), with symptoms of urge urinary incontinence, urgency and urinary frequency.

Zagreb, 31 May 2004

© 2019 PLIVA HRVATSKA d.o.o. / All rights reserved. / Legal information / Data protection and cookies / Impressum